Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of INCB054707 in prurigo nodularis
2021-006329-23Phase 2Active
- Sponsor
- Incyte
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of povorcitinib in prurigo nodularis (PN) (4 arms), sponsored by Incyte. Primary endpoint: Proportion of participants achieving ≥4-point improvement in Itch NRS score at Week 16. Started Dec 2021; status: active.
02
Drugs
povorcitinib
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2021-006329-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006329-23.